<SEC-DOCUMENT>0001209191-18-060083.txt : 20181127
<SEC-HEADER>0001209191-18-060083.hdr.sgml : 20181127
<ACCEPTANCE-DATETIME>20181127211100
ACCESSION NUMBER:		0001209191-18-060083
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20181127
FILED AS OF DATE:		20181127
DATE AS OF CHANGE:		20181127

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			MAULDIN JOHN F
		CENTRAL INDEX KEY:			0001522480

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38519
		FILM NUMBER:		181204054

	MAIL ADDRESS:	
		STREET 1:		3204 BEVERLY DRIVE
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75205

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AgeX Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001708599
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				821436829
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		1010 ATLANTIC AVENUE
		STREET 2:		SUITE 102
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94501
		BUSINESS PHONE:		510-521-3390

	MAIL ADDRESS:	
		STREET 1:		1010 ATLANTIC AVENUE
		STREET 2:		SUITE 102
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94501
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2018-11-27</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001708599</issuerCik>
        <issuerName>AgeX Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>AGE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001522480</rptOwnerCik>
            <rptOwnerName>MAULDIN JOHN F</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>2900 MCKINNON, #1708</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>DALLAS</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>75201</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Option to Purchase Common Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.50</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2028-05-24</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>35000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Will become exercisable in four equal quarterly installments after the date of grant on May 25, 2018.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/John F. Mauldin</signatureName>
        <signatureDate>2018-11-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
